Send to:

Choose Destination
See comment in PubMed Commons below
Gynecol Oncol. 2010 Feb;116(2):222-33. doi: 10.1016/j.ygyno.2009.11.001. Epub 2009 Dec 2.

The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Author information

  • 1Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.


In the past decade we have witnessed important advances in the treatment of gynecological cancers and have recognized their potential immunogenicity. This has opened the door to explore immune therapy not only in HPV-induced cancers but also in ovarian and endometrial cancers. Here we will review the off-target immune effects of select chemotherapy drugs commonly used to treat gynecologic cancers and novel tools that can stimulate both the adaptive and innate immune mechanisms such as novel pleiotropic cytokines, Toll-like receptors, and powerful antibodies that can target inhibitory checkpoints, thereby activating effector cellular immune mechanisms and neutralizing suppressor cells. We will also review how existing drugs can be used for combinatorial tumor therapy.

Published by Elsevier Inc.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk